Tap on **AVAILABLE IN BUNDLE / PACKAGE DEAL** to unlock free bonus exams and everything you need.
# NRNP 6675 MIDTERM EXAM QUESTIONS AND CORRECT VERIFIED SOLUTIONS LATEST UPDATE THIS YEAR – JUST RELEASED
Prepare for the **NRNP 6675 PMHNP Care Across the Lifespan II Midterm Examination** with a comprehensive study resource focused on advanced psychiatric assessment, diagnosis, psychopharmacology, therapeutic interventions, and clinical decision-making across the lifespan. Current 2026–2027 materials identify NRNP 6675 with **PMHNP Care Across the Lifespan II** and emphasize psychiatric disorders, medication management, treatment planning, and application of advanced psychiatric nursing concepts.
The guide emphasizes **exam-style questions with correct answers and detailed rationales**, helping learners connect psychiatric symptoms, diagnostic criteria, pharmacological mechanisms, treatment choices, adverse effects, and patient-specific clinical considerations. Questions are designed to reinforce both foundational knowledge and clinical reasoning.
A major focus is **advanced psychopharmacology**, including antipsychotics, antidepressants, mood stabilizers, anxiolytics, stimulants, and medications used for substance-related disorders. Preparation addresses mechanisms of action, receptor activity, therapeutic effects, adverse reactions, contraindications, drug interactions, monitoring requirements, patient education, and medication selection.
The resource provides extensive coverage of **antipsychotic medications and serious adverse reactions**, including dopamine pathways, positive and negative symptoms, extrapyramidal symptoms, akathisia, dystonia, parkinsonism, tardive dyskinesia, hyperprolactinemia, metabolic effects, and neuroleptic malignant syndrome. Recent 2026 midterm study materials specifically emphasize NMS risk factors and dopamine-receptor effects.
Preparation also addresses **substance-related and addictive disorders**, including intoxication and withdrawal syndromes, stimulant and depressant effects, opioid-related disorders, alcohol-related disorders, hallucinogens, dissociative substances, motivational interviewing, harm-reduction principles, medication-assisted treatment, relapse prevention, and appropriate levels of care.
The guide further reinforces **psychiatric assessment and diagnosis**, including comprehensive psychiatric history, mental-status examination, differential diagnosis, DSM-5-TR concepts, risk assessment, suicide and violence assessment, developmental considerations, medical and substance-induced psychiatric conditions, and interpretation of clinical findings.
Additional preparation covers **mood, anxiety, trauma-related, psychotic, and other psychiatric disorders**, with attention to symptom recognition, differential diagnosis, evidence-based treatment, psychotherapy considerations, medication management, follow-up, treatment response, and identification of worsening or emergent symptoms.
The material incorporates **lifespan-specific psychiatric care**, including developmental differences in children and adolescents, adult psychiatric presentations, older-adult mental health considerations, neurocognitive disorders, medication sensitivity, comorbidities, polypharmacy, and individualized treatment planning.
Scenario-based questions emphasize **advanced clinical judgment**, requiring learners to determine the most appropriate diagnosis, medication, intervention, monitoring strategy, patient education, or next clinical step based on symptoms, history, medications, laboratory findings, risk factors, and treatment response.
The guide also reinforces **ethical, legal, and professional responsibilities**, including informed consent, confidentiality, patient autonomy, safe prescribing, controlled-substance considerations, documentation, therapeutic boundaries, cultural responsiveness, interprofessional collaboration, and appropriate referral or escalation of care.
This resource is designed to support preparation for the **NRNP 6675 PMHNP Care Across the Lifespan II Midterm Examination** and is intended as a study and practice resource rather than a reproduction of the actual Walden University examination. It does not claim to contain confidential, leaked, copyrighted, or identical questions from a live examination, and it is not an official Walden University answer key.
Content preview
Page 1 of 122
NRNP 6675 MIDTERM EXAM QUESTIONS AND CORRECT
VERIFIED SOLUTIONS LATEST UPDATE THIS YEAR – JUST
RELEASED
NRNP 6675 MIDTERM EXAM
Exam Coverage
1. Psychiatric mental health assessment and the PMHNP role across the lifespan.
2. Neurobiology, neurotransmitters, receptors, and biological theories of psychiatric
disorders.
3. Antipsychotic medications, adverse effects, extrapyramidal symptoms, and neuroleptic
malignant syndrome.
4. Substance use disorders, intoxication, withdrawal, treatment principles, and commonly
misused substances.
5. Anxiety disorders, phobias, obsessive-compulsive and related disorders.
6. Schizophrenia spectrum and other psychotic disorders.
7. Personality disorders and characteristic clinical presentations.
8. Gender, sexuality, sexual disorders, and culturally responsive psychiatric care.
9. Professional practice, APRN competencies, ethics, scope of practice, and patient safety.
10. Epidemiology, risk factors, diagnostic reasoning, and evidence-based psychiatric
management.
1. A patient with schizophrenia has auditory hallucinations and prominent delusions. Which
neurotransmitter pathway is most strongly associated with these positive symptoms?
A. Mesocortical dopamine pathway
B. Mesolimbic dopamine pathway
C. Nigrostriatal dopamine pathway
D. Tuberoinfundibular dopamine pathway
, Page 2 of 122
Answer: B. Mesolimbic dopamine pathway
Rationale: Increased dopaminergic activity in the mesolimbic pathway is associated with
positive symptoms such as hallucinations and delusions.
2. Which neurotransmitter is most strongly associated with the pathophysiology and
treatment of obsessive-compulsive disorder?
A. Serotonin
B. Acetylcholine
C. Histamine
D. Glutamate only
Answer: A. Serotonin
Rationale: Serotonergic dysregulation is strongly implicated in OCD, which is one reason SSRIs
are first-line pharmacologic treatments.
3. A patient taking a high-potency typical antipsychotic develops severe muscle rigidity, fever,
altered consciousness, and autonomic instability. Which condition should the PMHNP
suspect?
A. Serotonin syndrome
B. Tardive dyskinesia
, Page 3 of 122
C. Neuroleptic malignant syndrome
D. Acute dystonia
Answer: C. Neuroleptic malignant syndrome
Rationale: NMS is a potentially fatal reaction characterized by severe rigidity, hyperthermia,
altered mental status, and autonomic dysfunction.
4. Which factor increases the risk for neuroleptic malignant syndrome?
A. Slow reduction of an antipsychotic dose
B. Rapid escalation of antipsychotic dosage
C. Long-term psychotherapy
D. Low-potency antipsychotic use only
Answer: B. Rapid escalation of antipsychotic dosage
Rationale: Rapid dose increases, high-potency antipsychotics, and parenteral administration can
increase NMS risk.
5. A patient taking an antipsychotic develops repetitive, involuntary movements of the
tongue, jaw, and mouth. Which adverse effect is most likely?
A. Akathisia
B. Acute dystonia
, Page 4 of 122
C. Tardive dyskinesia
D. Neuroleptic malignant syndrome
Answer: C. Tardive dyskinesia
Rationale: Tardive dyskinesia involves repetitive involuntary movements, commonly affecting
the mouth, tongue, jaw, and face after prolonged dopamine-blocking medication exposure.
6. Which medication is most commonly associated with the treatment of tardive dyskinesia?
A. Valbenazine
B. Benztropine
C. Propranolol
D. Lorazepam
Answer: A. Valbenazine
Rationale: Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for
tardive dyskinesia.
7. A patient taking an antipsychotic suddenly develops painful neck spasms and abnormal
positioning of the head. Which extrapyramidal symptom is most likely?
A. Akathisia
B. Acute dystonia